Alpine Immune Sciences, Inc. – NASDAQ:ALPN
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 8 hours
Alpine Immune Sciences stock price monthly change
+83.89%
month
Alpine Immune Sciences stock price quarterly change
+113.86%
quarter
Alpine Immune Sciences stock price yearly change
+657.23%
year
Alpine Immune Sciences key metrics
Market Cap | 4.45B |
Enterprise value | 252.61M |
P/E | -4.03 |
EV/Sales | 5.15 |
EV/EBITDA | -3.22 |
Price/Sales | 5.13 |
Price/Book | 1.40 |
PEG ratio | -0.31 |
EPS | -0.69 |
Revenue | 56.52M |
EBITDA | -45.41M |
Income | -36.83M |
Revenue Q/Q | -25.08% |
Revenue Y/Y | 118.88% |
Profit margin | -170.23% |
Oper. margin | -167.59% |
Gross margin | 0% |
EBIT margin | -167.59% |
EBITDA margin | -80.35% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAlpine Immune Sciences stock price history
Alpine Immune Sciences stock forecast
Alpine Immune Sciences financial statements
| Jun 2023 | 8.59M | -13.15M | -153.1% |
|---|---|---|---|
| Sep 2023 | 10.04M | -11.72M | -116.72% |
| Dec 2023 | 30.85M | 5.96M | 19.32% |
| Mar 2024 | 7.03M | -17.91M | -254.81% |
| Sep 2025 | 87.16M | -28.78M | -33.03% |
|---|---|---|---|
| Oct 2025 | 17.12M | -29.60M | -172.85% |
| Dec 2025 | 32.63M | -25.59M | -78.42% |
| Dec 2025 | 19.86M | -30.26M | -152.33% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 252836000 | 83.44M | 33% |
|---|---|---|---|
| Sep 2023 | 240547000 | 78.91M | 32.81% |
| Dec 2023 | 381812000 | 53.87M | 14.11% |
| Mar 2024 | 373646000 | 40.94M | 10.96% |
| Jun 2023 | -18.09M | 29.32M | 8.39M |
|---|---|---|---|
| Sep 2023 | -15.79M | -535K | 1.20M |
| Dec 2023 | -18.97M | -112.70M | 156.61M |
| Mar 2024 | -27.69M | -2.56M | 19.35M |
Alpine Immune Sciences alternative data
| Aug 2023 | 126 |
|---|---|
| Sep 2023 | 126 |
| Oct 2023 | 126 |
| Nov 2023 | 126 |
| Dec 2023 | 126 |
| Jan 2024 | 126 |
| Feb 2024 | 126 |
| Mar 2024 | 142 |
| Apr 2024 | 142 |
| May 2024 | 142 |
| Jun 2024 | 142 |
| Jul 2024 | 142 |
Alpine Immune Sciences other data
10.86%
-89.14%
of ALPN is owned by hedge funds
27
-35
3.63M
-30.58M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2023 | 375000 | 18703 |
| Dec 2023 | 0 | 3418357 |
| Jan 2024 | 0 | 118000 |
| Apr 2024 | 0 | 19 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | PENG STANFORD L officer: See Rema.. | Common Stock | 37,267 | $0.65 | $24,224 | ||
Option | DURAND REMY officer: Chief Business Officer | Common Stock | 10,000 | $4.76 | $47,600 | ||
Option | PENG STANFORD L officer: See Rema.. | Common Stock | 13,377 | $6.33 | $84,676 | ||
Option | PENG STANFORD L officer: See Rema.. | Common Stock | 26,912 | $3.23 | $86,926 | ||
Option | GOLD MITCHELL director, officer.. | Stock Option (Right to buy) | 13,245 | $7.55 | $100,000 | ||
Option | GOLD MITCHELL director, officer.. | Common Stock | 13,245 | $7.55 | $100,000 | ||
Option | FUHS ULRICH MARTIN officer: Chief Accounting Officer | Stock Option (Right to buy) | 22,820 | $12.07 | $275,437 | ||
Option | FUHS ULRICH MARTIN officer: Chief Accounting Officer | Common Stock | 22,820 | $12.07 | $275,437 | ||
Option | PENG STANFORD L officer: See Rema.. | Stock Option (Right to buy) | 13,377 | $6.33 | $84,676 | ||
Option | PENG STANFORD L officer: See Rema.. | Stock Option (Right to buy) | 7,025 | $13.2 | $92,730 |
| Patent |
|---|
Application Filling date: 29 Mar 2022 Issue date: 4 Aug 2022 |
Application Filling date: 16 Apr 2020 Issue date: 14 Jul 2022 |
Grant Filling date: 11 Jun 2021 Issue date: 14 Jun 2022 |
Application Filling date: 19 Sep 2019 Issue date: 9 Jun 2022 |
Application Filling date: 2 Feb 2022 Issue date: 26 May 2022 |
Application Filling date: 2 Feb 2022 Issue date: 19 May 2022 |
Grant Filling date: 15 Apr 2016 Issue date: 3 May 2022 |
Application Filling date: 22 Dec 2021 Issue date: 14 Apr 2022 |
Grant Filling date: 11 Jun 2021 Issue date: 15 Mar 2022 |
Grant Filling date: 28 Jan 2021 Issue date: 25 Jan 2022 |
| Quarter | Transcript |
|---|---|
| Q4 2023 18 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q4 2022 23 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 14 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2021 10 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Mitchell H. Gold M.D. (1968) Executive Chairman & Chief Executive Officer | $817,500 |
| Dr. Stanford Peng M.D., Ph.D. (1971) Pres and Head of R&D | $758,640 |
Mr. Paul Rickey (1979) Senior Vice President, Chief Financial Officer, Treasurer & Sec. | $551,800 |
Alpine Immune Sciences: November 2023 Data Release Could Get Ball Rolling
Alpine Immune: Rebuilding Itself From Scratch, But Long Way To Go Before Proof
Alpine Immune Sciences: ALPN-202 May Be Dead, But The Company Isn't
Alpine: Ramifications Of The Davoceticept Termination
Alpine: Rest Before Rallying Again
Celldex: Powerful Medicines To Yield Further Upsides
ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas
Alpine Immune Sciences: Better Days Ahead
Alpine Immune Sciences Is A Blind Buy After The Recent Price Decrease
-
When is Alpine Immune Sciences's next earnings date?
Unfortunately, Alpine Immune Sciences's (ALPN) next earnings date is currently unknown.
-
Does Alpine Immune Sciences pay dividends?
No, Alpine Immune Sciences does not pay dividends.
-
How much money does Alpine Immune Sciences make?
Alpine Immune Sciences has a market capitalization of 4.45B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 95.84% to 58.88M US dollars.
-
What is Alpine Immune Sciences's stock symbol?
Alpine Immune Sciences, Inc. is traded on the NASDAQ under the ticker symbol "ALPN".
-
What is Alpine Immune Sciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Alpine Immune Sciences?
Shares of Alpine Immune Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Alpine Immune Sciences's key executives?
Alpine Immune Sciences's management team includes the following people:
- Dr. Mitchell H. Gold M.D. Executive Chairman & Chief Executive Officer(age: 57, pay: $817,500)
- Dr. Stanford Peng M.D., Ph.D. Pres and Head of R&D(age: 54, pay: $758,640)
- Mr. Paul Rickey Senior Vice President, Chief Financial Officer, Treasurer & Sec.(age: 46, pay: $551,800)
-
How many employees does Alpine Immune Sciences have?
As Jul 2024, Alpine Immune Sciences employs 142 workers.
-
When Alpine Immune Sciences went public?
Alpine Immune Sciences, Inc. is publicly traded company for more then 10 years since IPO on 17 Jun 2015.
-
What is Alpine Immune Sciences's official website?
The official website for Alpine Immune Sciences is alpineimmunesciences.com.
-
Where are Alpine Immune Sciences's headquarters?
Alpine Immune Sciences is headquartered at 188 East Blaine Street, Seattle, WA.
-
How can i contact Alpine Immune Sciences?
Alpine Immune Sciences's mailing address is 188 East Blaine Street, Seattle, WA and company can be reached via phone at +20 67 884545.
Alpine Immune Sciences company profile:
Alpine Immune Sciences, Inc.
alpineimmunesciences.comExchange:
NASDAQ
Full time employees:
142
Industry:
Biotechnology
Sector:
Healthcare
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
188 East Blaine Street
Seattle, WA 98102
Seattle, WA 98102
CIK: 0001626199
ISIN: US02083G1004
CUSIP: 02083G100
